Sage, Biogen Report Results From Phase 2 KINETIC 2 Study Of SAGE-324 (BIIB124) For Essential Tremor; Did Not Demonstrate Statistically Significant Dose-Response Relationship On Primary Endpoint
Portfolio Pulse from Benzinga Newsdesk
Sage Therapeutics and Biogen reported results from their Phase 2 KINETIC 2 study of SAGE-324 (BIIB124) for essential tremor. The study did not demonstrate a statistically significant dose-response relationship on the primary endpoint.
July 24, 2024 | 10:34 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Biogen, in collaboration with Sage Therapeutics, reported that their Phase 2 study of SAGE-324 did not meet its primary endpoint, which could negatively impact Biogen's stock price in the short term.
The unsuccessful Phase 2 study of SAGE-324, a collaborative effort with Sage Therapeutics, is likely to negatively affect Biogen's stock price due to the setback in their drug development pipeline.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80
NEGATIVE IMPACT
Sage Therapeutics' Phase 2 KINETIC 2 study of SAGE-324 did not meet its primary endpoint, which could negatively impact investor sentiment and the stock price in the short term.
The failure to demonstrate a statistically significant dose-response relationship in the Phase 2 study is a setback for Sage Therapeutics, likely leading to negative investor sentiment and a potential drop in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100